Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04573777 · ClinicalTrials.gov registry record · Phase 4
Reducing Intracranial atheroSclErosis With Repatha
A Phase 4 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04573777 is a Phase 4 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 10 participants.
The verdict
NCT04573777, a Phase 4 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study will be to understand the underlying mechanism by which PCSK9 inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing atherosclerotic plaque, which would be particularly beneficial for patients with intracranial atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.
Interventions
- DRUG Repatha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-04-23 |
| Est. Completion | 2021-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04573777
The ClinicalTrials.gov registry entry for NCT04573777 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Repatha is the first listed.
NCT04573777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04573777 about?
NCT04573777 is a clinical study titled "Reducing Intracranial atheroSclErosis With Repatha". The purpose of this study will be to understand the underlying mechanism by which PCSK9 inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled almost 50,000 patients and sh...
What is the current status of trial NCT04573777?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2021-04-23. Estimated completion is 2021-12-16.
What interventions are being tested in trial NCT04573777?
The interventions under investigation include: Repatha (DRUG).
Who is sponsoring clinical trial NCT04573777?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.